The HHS international reference pricing proposal to lower costs for Medicare Part B drugs may be more likely to be used by the administration to strike a deal with Congress than to be implemented, according to former long-time Republican congressional staffer and McDermott Consulting VP Rodney Whitlock.
“Right now it feels like what the administration is doing, particularly with this proposal and several others in the drug...